Lze zlepšit komplianci pacientů k dlouhodobé terapii statiny?

SOŠKA, Vladimír a Ondřej KYSELÁK. Lze zlepšit komplianci pacientů k dlouhodobé terapii statiny? Vnitřní lékařství. Praha: Česká lékařská společnost J.E. Purkyně, 2017, roč. 63, č. 10, s. 663-666. ISSN 0042-773X.

Základní údaje

Originální název

Lze zlepšit komplianci pacientů k dlouhodobé terapii statiny?

Název anglicky

Is it possible to improve long-term compliance of patients to statin therapy?

Autoři

SOŠKA, Vladimír (203 Česká republika, garant, domácí) a Ondřej KYSELÁK (203 Česká republika)

Vydání

Vnitřní lékařství, Praha, Česká lékařská společnost J.E. Purkyně, 2017, 0042-773X

---

Další údaje

Jazyk

čeština

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/17:00098601

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Compliance; Creatinkinase; Diabetes mellitus; Ldl-cholesterol; Statins

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

---

Anotace

V originále

Statins are key drugs for patients in secondary prevention of cardiovascular disease, as well as for primary prevention patients at high or very high risk of fatal cardiovascular events. However, long-term compliance of patients to statin therapy is relatively low, decreasing with the time of statin use; moreover a significant proportion of patients stop statins medication over the course of several years. To the early termination of statin treatment often contributes apprehension of the occurence of statin's side effects (i.g. increased creatine kinase in the blood and muscle problems), although these symptoms are usually not causally related to statin therapy. To the low compliance may also contribute administration of statins in the evening hours, as well as the fear of developing diabetes or drug interactions. The above issues are discussed in the text of this article.

Anglicky

Statins are key drugs for patients in secondary prevention of cardiovascular disease, as well as for primary prevention patients at high or very high risk of fatal cardiovascular events. However, long-term compliance of patients to statin therapy is relatively low, decreasing with the time of statin use; moreover a significant proportion of patients stop statins medication over the course of several years. To the early termination of statin treatment often contributes apprehension of the occurence of statin's side effects (i.g. increased creatine kinase in the blood and muscle problems), although these symptoms are usually not causally related to statin therapy. To the low compliance may also contribute administration of statins in the evening hours, as well as the fear of developing diabetes or drug interactions. The above issues are discussed in the text of this article.